Ipamorelin vs CJC-1295
Compare the research profiles of Ipamorelin and CJC-1295. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesIpamorelin
Ipamorelin
Category
growth-hormone
Research Level
Phase 2 Clinical Trials
FDA Status
not-approved
CJC-1295
CJC-1295 (with or without DAC)
Category
growth-hormone
Research Level
Phase 2 Clinical Trials
FDA Status
not-approved
Detailed Comparison
| Aspect | Ipamorelin | CJC-1295 |
|---|---|---|
| Overview | A growth hormone releasing peptide (GHRP) that stimulates natural GH production. Popular for its selectivity - it doesn't significantly affect cortisol or prolactin levels.... | A growth hormone releasing hormone (GHRH) analog that stimulates GH release. Available with DAC (Drug Affinity Complex) for extended half-life or without for shorter action.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Binds to ghrelin receptors in the pituitary gland, stimulating the release of growth hormone. More selective than other GHRPs with fewer side effects.... | Mimics GHRH to stimulate the pituitary gland to produce and release growth hormone. The DAC version binds to albumin for prolonged effect.... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.